HOME >> BIOLOGY >> NEWS
Immunex Corporation and Genentech, Inc. join forces to develop TRAIL/Apo2L in cancer

SEATTLE and SOUTH SAN FRANCISCO, June 1, 1999- Immunex Corporation (NASDAQ: IMNX) and Genentech, Inc. (NYSE:GNE) announced today that the two companies agreed to jointly develop TRAIL/Apo2L, an entirely new approach to research in the fight against cancer. Pending FDA approval, the companies have also agreed to jointly commercialize the product.

"Combining our world class leadership in science and pharmaceutical development enhances our ability to more efficiently evaluate TRAIL/Apo2L and its potential to fight cancer," said Arthur D. Levinson, PhD, Genentech president and CEO, and Ed Fritzky, Immunex chairman and CEO, in a joint statement. "Should the science and clinical studies prove consistent with the preclinical findings that the molecule has already shown, our companies are poised to move to the next level of development with this new technology."

Immunex and Genentech have each conducted extensive preclinical testing of different forms of TRAIL/Apo2L. TRAIL/Apo2L, also known as TNF-related apoptosis-inducing ligand, appears in animal models to suppress tumor growth and causes remission of tumors, by a direct and specific mechanism known as apoptosis, or programmed cell death. TRAIL/Apo2L binds to at least four distinct receptors found on many tumor cells and signals these cells to destroy themselves through apoptosis. In preclinical research, TRAIL/Apo2L has been shown to cause a wide variety of tumor cells to undergo apoptosis while sparing normal cells. Preclinical studies have not identified significant toxicities from TRAIL/Apo2L administration.

The companies will form a joint steering committee and project team to select a single lead molecule for development, manage the development process, and allocate clinical, manufacturing and marketing responsibilities to each company. Immunex and Genentech each have filed patent applications covering TRAIL/Apo2L and its uses, and Immunex was awarded a patent coveri
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
1-Jun-1999


Page: 1 2

Related biology news :

1. UWs new Cell Systems Initiative welcomes Immunex collaboration
2. Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure
3. Corporations and environmentalists can be allies to reduce industrys ecological footprint
4. UCSD-Salk Institute awards presented to Christopher Reeve, Dr. Donald Seldin, Genentech, Inc. and Dr. Dennis Slamon
5. East Asian governments urged to harness market forces to improve environment, save money
6. NYAS and Nature Publishing Group join forces
7. Foundations join forces to find a cure or treatment for deadly genetic disease
8. Foundations join forces to finance research for Canavan disease
9. Whats next as biology, math combine forces, reciprocate in discovery
10. Fluid forces within the body help invasive bacteria
11. Disorder forces DNA molecules out of tight spaces

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: